Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: A randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization

Cancer

Volumn 116, Issue 23, 2010, Pages 5452-5460

  Morimoto, Manabu ^a   Numata, Kazushi ^a   Kondou, Masaaki ^a   Nozaki, Akito ^a   Morita, Satoshi ^a   Tanaka, Katsuaki ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

combination therapy; hepatocellular carcinoma; local tumor progression; radiofrequency ablation; survival; transcatheter arterial chemoembolization

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SIZE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; LIVER CELL CARCINOMA; LIVER FUNCTION; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PLEURA EFFUSION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; SAFETY; SURVIVAL RATE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 78649570066     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25314     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
2. Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology. 2005; 235: 728-739.
3. Ikai I, Arii S, Okazaki M, et al. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res. 2007; 37: 676-691.
4. Bruix J, Sherman M,. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208-1236.
5. Ebara M, Ohto M, Sugiura N, et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol. 1990; 5: 616-626.
6. Castells A, Bruix J, Bru C, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology. 1993; 18: 1121-1126.
7. Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am. 1995; 1: 73-81.
8. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS,. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999; 210: 655-661.
9. Morimoto M, Sugimori K, Shirato K, et al. Treatment of hepatocellular carcinoma with radiofrequency ablation: radiologic-histologic correlation during follow-up periods. Hepatology. 2002; 35: 1467-1475.
10. Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology. 2000; 214: 761-768.
11. Livraghi T, Goldberg SN, Monti F, et al. Saline-enhanced radio-frequency tissue ablation in the treatment of liver metastases. Radiology. 1997; 202: 205-210.
12. Kurokohchi K, Watanabe S, Masaki T, et al. Combination therapy of percutaneous ethanol injection and radiofrequency ablation against hepatocellular carcinomas difficult to treat. Int J Oncol. 2002; 21: 611-615.
13. de Baere T, Bessoud B, Dromain C, et al. Percutaneous radiofrequency ablation of hepatic tumors during temporary venous occlusion. AJR Am J Roentgenol. 2002; 178: 53-59.
14. Kobayashi M, Ikeda K, Kawamura Y, et al. Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma-direct ablative effects and a long-term outcome. Liver Int. 2007; 27: 353-359.
15. Yamakado K, Nakatsuka A, Ohmori S, et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol. 2002; 13: 1225-1232.
16. Sugimori K, Morimoto M, Shirato K, et al. Radiofrequency ablation in a pig liver model: effect of transcatheter arterial embolization on coagulation diameter and histologic characteristics. Hepatol Res. 2002; 24: 164-173.
17. Bloomston M, Binitie O, Fraiji E, et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg. 2002; 68: 827-831.
18. Lau H, Fan ST, Ng IO, Wong J,. Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients. Cancer. 1998; 83: 2302-2311.
19. Shirato K, Morimoto M, Tomita N, et al. Hepatocellular carcinoma: percutaneous radiofrequency ablation using expandable needle electrodes and the double-insertion technique. Hepatogastroenterology. 2002; 49: 1481-1483. (Pubitemid 35277303)
20. Sacks D, McClenny TE, Cardella JF, Lewis CA,. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol. 2003; 14 (9 pt 2): S199-S202.
21. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P,. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000; 232: 381-391.
22. Allgaier HP, Deibert P, Zuber I, Olschewski M, Blum HE,. Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma. Lancet. 1999; 353: 1676-1677.
23. Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer. 1994; 74: 817-825. (Pubitemid 24237460)
24. Rossi S, Garbagnati F, Lencioni R, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology. 2000; 217: 119-126.
25. Nakamura H, Hashimoto T, Oi H, et al. Treatment of hepatocellular carcinoma by segmental hepatic artery injection of adriamycin-in-oil emulsion with overflow to segmental portal veins. Acta Radiol. 1990; 31: 347-349.
26. Goldberg SN, Saldinger PF, Gazelle GS, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intratumoral doxorubicin injection in a rat breast tumor model. Radiology. 2001; 220: 420-427.
27. Goldberg SN, Girnan GD, Lukyanov AN, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology. 2002; 222: 797-804.
28. Goldberg SN, Kamel IR, Kruskal JB, et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. AJR Am J Roentgenol. 2002; 179: 93-101.
29. Holdener EE, Hansen HH, Host H, et al. Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC). Invest New Drugs. 1985; 3: 63-66.
30. Buscarini L, Buscarini E, Di Stasi M, Quaretti P, Zangrandi A,. Percutaneous radiofrequency thermal ablation combined with transcatheter arterial embolization in the treatment of large hepatocellular carcinoma. Ultraschall Med. 1999; 20: 47-53.
31. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G,. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol. 2006; 16: 661-669.
32. Yu SC, Leung TW, Lau WY, et al. A comparison of 3 transarterial lipiodol-based formulations for hepatocellular carcinoma: in vivo biodistribution study in humans. Cardiovasc Intervent Radiol. 2008; 31: 289-298.
33. Kumada T, Nakano S, Takeda I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 1997; 25: 87-92.
34. Koike Y, Shiratori Y, Sato S, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001; 91: 561-569.
35. Okusaka T, Okada S, Ueno H, et al. Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma. Oncology. 2000; 58: 293-299.
36. Tateishi R, Shiina S, Yoshida H, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using 3 tumor markers. Hepatology. 2006; 44: 1518-1527.
37. Ebara M, Ohto M, Shinagawa T, et al. Natural history of minute hepatocellular carcinoma smaller than 3 centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology. 1986; 90: 289-298.
38. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993; 18: 47-53.
39. Taketa K,. Alpha-fetoprotein: reevaluation in hepatology. Hepatology. 1990; 12: 1420-1432.
40. Aoyagi Y, Isemura M, Yosizawa Z, et al. Fucosylation of serum alpha-fetoprotein in patients with primary hepatocellular carcinoma. Biochim Biophys Acta. 1985; 830: 217-223.
41. Yamashita F, Tanaka M, Satomura S, Tanikawa K,. Monitoring of lectin-reactive alpha-fetoproteins in patients with hepatocellular carcinoma treated using transcatheter arterial embolization. Eur J Gastroenterol Hepatol. 1995; 7: 627-633.
42. Ogawa C, Kudo M, Minami Y, Chung H, Kawasaki T,. Tumor markers after radiofrequency ablation therapy for hepatocellular carcinoma. Hepatogastroenterology. 2008; 55: 1454-1457.
43. Takahashi S, Kudo M, Chung H, et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology. 2007; 72 (suppl 1): 98-103.
44. Morimoto M, Numata K, Sugimori K, et al. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol. 2007; 13: 1003-1009.